J. Lahmar

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

Laura Mezquita, Édouard Auclin, Roberto Ferrara et al. · JAMA Oncology · 2018 · 951 citations · Full text

Life Sciences, Immunology, Oncology +17

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Roberto Ferrara, Laura Mezquita, Matthieu Texier et al. · JAMA Oncology · 2018 · 738 citations · Full text

Medicine, Oncology, Pharmacology +14

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

Mélodie Tazdait, Laura Mezquita, J. Lahmar et al. · European Journal of Cancer · 2017 · 351 citations

Medicine, Oncology, Immunotherapy +14

Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non–Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy

Roberto Ferrara, Laura Mezquita, Matthieu Texier et al. · JCO Precision Oncology · 2020 · 37 citations · Full text

Medicine, Oncology, Pharmacology +17

Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO)

Roberto Ferrara, Caroline Caramella, Matthieu Texier et al. · Annals of Oncology · 2017 · 28 citations · Full text

Medicine, Immunology, Oncology +14